#ASH25 | @RabiHannaMD of @ClevelandClinic shares updated results from the RUBY trial, which is investigating reni-cel, an investigational gene-edited autologous hematopoietic stem cell therapy, in patients with severe #SickleCellDisease:

🎥 ➡️ …

Reni-cel in severe SCD: updated results from the RUBY trial

Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares updated results from the RUBY trial (NCT04853576), which is ...

ow.ly

It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma!

🎥 👉

Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier…

Bispecific antibodies in myeloma: top trial updates from ASH 2025

In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses his highlights in multiple my...

ow.ly

Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔

Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25:

🎥…

At #ASH25, @pongasg of @SylvesterCancer shared insight into the ongoing Phase II TaZa CLL study investigating tafasitamab and zanubrutinib in newly diagnosed patients with CLL.

Click here to watch the interview:

👉 👈

#CLLsm #Leusm #Leukemia #CTSM…

TaZa CLL: tafasitamab and zanubrutinib in newly diagnosed CLL

Georgios Pongas, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of t...

ow.ly

Thank you to @Mohty_EBMT for stopping by at #ASH25 last week to share insight into the key advances & developments in GvHD management presented at the meeting!🩸

Watch the interview by clicking here:
👉 👈

#BMTsm #AMLsm #MDSsm #Myelofibrosis #HemOnc…

Advances in GvHD management presented at ASH 2025

In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses key advances and development...

ow.ly